Varicella‐Zoster Virus–Specific Cell‐Mediated Immunity in HIV‐Infected Children Receiving Highly Active Antiretroviral Therapy | Zendy

Adriana Weinberg | Zendy; Andrew Wiznia | Zendy; Bonnie LaFleur | Zendy; Sona Shah | Zendy; Myron J. Levin | Zendy

Open Access

Varicella‐Zoster Virus–Specific Cell‐Mediated Immunity in HIV‐Infected Children Receiving Highly Active Antiretroviral Therapy

Author(s) -

Adriana Weinberg,

Andrew Wiznia,

Bonnie LaFleur,

Sona Shah,

Myron J. Levin

Publication year - 2004

Publication title -

the journal of infectious diseases

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/422011

Subject(s) - virology , immunity , antiretroviral therapy , medicine , virus , varicella zoster virus , cell mediated immunity , immunology , human immunodeficiency virus (hiv) , immune system , viral load

Herpes zoster (HZ) is a frequent complication of advanced human immunodeficiency virus (HIV) infection. We determined the effect of highly active antiretroviral therapy (HAART) on reconstitution of varicella-zoster virus (VZV)-specific cell-mediated immunity (VZV-CMI) in 56 VZV- and HIV-infected children. VZV-CMI did not change over the course of >/=3 years of observation, despite a reduction in HIV load. VZV-CMI correlated with lower HIV load but not with CD4 cell percentage. The incidence of HZ was unaffected by HAART. None of 5 patients who developed HZ during the study had VZV-CMI before developing HZ. After developing HZ, only the 2 HAART-compliant patients developed VZV-CMI. Thus, VZV-specific immune reconstitution in HIV infection may require antigenic reexposure, in addition to control of HIV replication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research